Search results for "M1"

showing 10 items of 837 documents

Oridonin Targets Multiple Drug-Resistant Tumor Cells as Determined by in Silico and in Vitro Analyses

2018

Drug resistance is one of the main reasons of chemotherapy failure. Therefore, overcoming drug resistance is an invaluable approach to identify novel anticancer drugs that have the potential to bypass or overcome resistance to established drugs and to substantially increase life span of cancer patients for effective chemotherapy. Oridonin is a cytotoxic diterpenoid isolated from Rabdosia rubescens with in vivo anticancer activity. In the present study, we evaluated the cytotoxicity of oridonin toward a panel of drug-resistant cancer cells overexpressing ABCB1, ABCG2, or ΔEGFR or with a knockout deletion of TP53. Interestingly, oridonin revealed lower degree of resistance than the control dr…

0301 basic medicineDrug resistancenatural compound03 medical and health sciences0302 clinical medicineIn vivomedicinePharmacology (medical)DoxorubicinProtein kinase BPI3K/AKT/mTOR pathwayOriginal ResearchPharmacologydrug resistanceChemistrylcsh:RM1-950molecular dockingmolecular dynamics030104 developmental biologylcsh:Therapeutics. PharmacologyDocking (molecular)030220 oncology & carcinogenesisPharmacogenomicsCancer cellCancer researchmicroarraymedicine.drugcluster analysisFrontiers in Pharmacology
researchProduct

Functional characterization of circulating tumor cells (CTCs) from metastatic ER+/HER2− breast cancer reveals dependence on HER2 and FOXM1 for endocr…

2021

Simple Summary Acquired endocrine resistance and late recurrence in patients with ER+/HER2− breast cancer are complex and not fully understood. Here, we evaluated mechanisms of acquired resistance in circulating tumor cells (CTCs) from an ER+/HER2− breast cancer patient who initially responded but later progressed under endocrine treatment. We found a switch from ERα-dependent to HER2-dependent and ERα-independent expression of FOXM1, which may enable disseminated ER+/HER2− cells to re-initiate tumor cell growth and metastasis formation in the presence of endocrine treatment. We found that NFkB signaling sustains HER2 and FOXM1 expression in CTCs in the presence of ERα inhibitors suggesting…

0301 basic medicineDrugLife sciences; biologyCancer Researchmedia_common.quotation_subjectTumor cellslcsh:RC254-282Article03 medical and health sciencesTherapeutic approach0302 clinical medicineCirculating tumor cellBreast cancerHER2-dependent FOXM1 expressionddc:570ER+/HER2− circulating tumor cellsMedicineEndocrine systemskin and connective tissue diseasesmedia_commonER+/HER2��� circulating tumor cellsbusiness.industryendocrine therapy resistancelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncologyApoptosis030220 oncology & carcinogenesisFOXM1Cancer researchbusiness
researchProduct

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.

2019

Introduction: The advent of biologic agents has revolutionized therapeutic approaches in systemic juvenile idiopatic arthritis (sJIA) as their introduction has been shown to modify disease course and improve overall outcomes, particularly when initiated early. Few studies have reported the drug retention rate (DRR) of biologic drugs in JIA, and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on sJIA. Objectives: The primary aim of the study was to examine the overall DRR of IL-1 blockers in sJIA patients. Secondary aims of our study were to: (i) explore the influence of biologic line of treatment, adverse events (AEs), type of anti-IL-1 agent and the conc…

0301 basic medicineDrugmedicine.medical_specialtysystemic juvenile idiopathic arthritismedia_common.quotation_subjectArthritisanakinra; canakinumab; drug retention rate; interleukin 1-beta; systemic juvenile idiopathic arthritis; therapycanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInterleukin-1 inhibitors Systemic Juvenile Idiopathic Arthritis Anakinra CanakinumabInternal medicineinterleukin 1-betaMedicinePharmacology (medical)Adverse effectmedia_commonOriginal ResearchPharmacologyAnakinraAnakinra Canakinumab Drug retention rate Interleukin 1-beta Systemic juvenile idiopathic arthritis Therapytherapybusiness.industrylcsh:RM1-950Hazard ratioInterleukinJuvenile idiopathic arthritisRetention ratemedicine.diseaseCanakinumablcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisSystemic juvenile idiopathic arthritidrug retention ratebusinessmedicine.druganakinraFrontiers in pharmacology
researchProduct

Beneficial Role of Exercise in the Modulation of

2021

Duchenne muscular dystrophy (DMD) is an X-linked recessive progressive lethal disorder caused by the lack of dystrophin, which determines myofibers mechanical instability, oxidative stress, inflammation, and susceptibility to contraction-induced injuries. Unfortunately, at present, there is no efficient therapy for DMD. Beyond several promising gene- and stem cells-based strategies under investigation, physical activity may represent a valid noninvasive therapeutic approach to slow down the progression of the pathology. However, ethical issues, the limited number of studies in humans and the lack of consistency of the investigated training interventions generate loss of consensus regarding …

0301 basic medicineDuchenne muscular dystrophyPhysiologyDuchenne muscular dystrophyClinical BiochemistryInflammationReviewBioinformaticsmedicine.disease_causeBiochemistrySettore BIO/09 - FisiologiaMuscle hypertrophy03 medical and health sciencesTherapeutic approach0302 clinical medicineFibrosismedicineTrainingMuscle inflammationVoluntary exerciseMolecular BiologySwimmingbiologybusiness.industrylcsh:RM1-950ROSCell Biologymedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyantioxidantsTreadmill runningbiology.proteinmedicine.symptomAntioxidantDystrophinExercise prescriptionbusiness030217 neurology & neurosurgeryOxidative stressAntioxidants (Basel, Switzerland)
researchProduct

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates

2016

Locked nucleic acid (LNA) oligonucleotides have been successfully used to efficiently inhibit endogenous small noncoding RNAs in vitro and in vivo. We previously demonstrated that the direct miR-221 inhibition by the novel 13-mer LNA-i-miR-221 induces significant antimyeloma activity and upregulates canonical miR-221 targets in vitro and in vivo. To evaluate the LNA-i-miR-221 pharmacokinetics and pharmacodynamics, novel assays for oligonucleotides quantification in NOD.SCID mice and Cynomolgus monkeys (Macaca fascicularis) plasma, urine and tissues were developed. To this aim, a liquid chromatography/mass spectrometry method, after solid-phase extraction, was used for the detection of LNA-i…

0301 basic medicineEndogenyIn situ hybridizationBiologyPharmacology03 medical and health sciencesPharmacokineticsDownregulation and upregulationIn vivoDrug DiscoveryLocked nucleic acidLNA inhibitormicroRNAOligonucleotidelcsh:RM1-950Cynomolgus monkeysCynomolgus monkeys LNA inhibitor MicroRNA MiRNA therapeutics Multiple myelomamiRNA therapeuticsMolecular biologyIn vitromultiple myelomalcsh:Therapeutics. Pharmacology030104 developmental biologyMolecular MedicineOriginal ArticleErratumMolecular Therapy - Nucleic Acids
researchProduct

Protective and regenerative effects of a novel medical device against esophageal mucosal damage using in vitro and ex vivo models.

2020

Gastroesophageal reflux disease (GERD) is a common digestive disorder that causes esophagitis and injuries to the esophageal mucosa. GERD symptoms are recurrent during pregnancy and their treatment is focused on lifestyle changes and nonprescription medicines. The aim of this study was to characterize the mechanism of action of a new patented medical device, an oral formulation containing hyaluronic acid, rice extract, and amino acids dispersed in a bioadhesive polymer matrix, by assessing its protective effects in in vitro and ex vivo models of esophageal mucosa damage. Acidic bile salts and pepsin cocktail (BSC) added to CP-A and COLO-680 N esophagus cells were used as an in vitro GERD mo…

0301 basic medicineEsophageal MucosaHyaluronic acidRM1-950PharmacologyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePepsinCell Line TumorDigestive disorderHyaluronic acidMedicineHumansRegenerationEsophagusAmino AcidsHyaluronic AcidEvans BlueMedical devicePharmacologybiologybusiness.industryBioadhesive polymer; Gastroesophageal reflux disease (GERD); Hyaluronic acid; Medical device; Rice extractPlant ExtractsRice extractAdhesivenessOryzaGeneral MedicineBioadhesive polymermedicine.diseaseGastroesophageal reflux disease (GERD)digestive system diseases030104 developmental biologymedicine.anatomical_structurechemistryEquipment and Supplies030220 oncology & carcinogenesisbiology.proteinGERDGastroesophageal RefluxTherapeutics. PharmacologybusinessWound healingEx vivoBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker.

2019

Abstract Alzheimer’s disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. M…

0301 basic medicineFarmacologiaADAM10DiseaseRM1-950Natural compoundsCleavage (embryo)NeuroprotectionCatechin03 medical and health sciencesADAM10 ProteinAmyloid beta-Protein Precursor0302 clinical medicineAlzheimer DiseaseDisintegrinHumansSenile plaquesPharmacological modulationPharmacologyMetalloproteinaseAmyloid beta-PeptidesbiologyChemistryPlant ExtractsADAM10ProteinsGinkgo bilobaMembrane ProteinsGeneral Medicineα-SecretaseAlzheimer's disease030104 developmental biologyMalaltia d'AlzheimerNeuroprotective Agents030220 oncology & carcinogenesisPharmaceuticalbiology.proteinTherapeutics. PharmacologyAmyloid Precursor Protein SecretasesNeuroscienceAlzheimer’s diseaseProteïnesBiomarkersBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

Annexin A2-Mediated Plasminogen Activation in Endothelial Cells Contributes to the Proangiogenic Effect of Adenosine A2A Receptors

2021

Adenosine A2A receptor mediates the promotion of wound healing and revascularization of injured tissue, in healthy and animals with impaired wound healing, through a mechanism depending upon tissue plasminogen activator (tPA), a component of the fibrinolytic system. In order to evaluate the contribution of plasmin generation in the proangiogenic effect of adenosine A2A receptor activation, we determined the expression and secretion of t-PA, urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and annexin A2 by human dermal microvascular endothelial cells stimulated by the selective agonist CGS-21680. The plasmin generation was assayed through an enzymatic assay a…

0301 basic medicineFarmacologiaAngiogenesisPlasminmedicine.medical_treatmentVasodilatadorsAdenosine A2A receptorRM1-950030204 cardiovascular system & hematologyTissue plasminogen activatormicrovascular endothelial cells03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrinolysismedicinePharmacology (medical)urokinase plasminogen activatorPharmacologytissue plasminogen activatorChemistryBrief Research Reportannexin A2adenosine receptorsCell biology030104 developmental biologyPlasminogen activator inhibitor-1plasminogen activator inhibitor-1Therapeutics. PharmacologyPlasminogen activatorProteïnesAnnexin A2medicine.drug
researchProduct

Increased Motor-Impairing Effects of the Neuroactive Steroid Pregnanolone in Mice with Targeted Inactivation of the GABAA Receptor γ2 Subunit in the …

2016

Endogenous neurosteroids and neuroactive steroids have potent and widespread actions on the brain via inhibitory GABAA receptors. In recombinant receptors and genetic mouse models their actions depend on the α, β, and δ subunits of the receptor, especially on those that form extrasynaptic GABAA receptors responsible for non-synaptic (tonic) inhibition, but they also act on synaptically enriched γ2 subunit-containing receptors and even on αβ binary receptors. Here we tested whether behavioral sensitivity to the neuroactive steroid agonist 5β-pregnan-3α-ol-20-one is altered in genetically engineered mouse models that have deficient GABAA receptor-mediated synaptic inhibition in selected neuro…

0301 basic medicineGAMMA-2-SUBUNITCerebellumNeuroactive steroidcerebellumDISORDERSPurkinje cellINHIBITIONBiologyPharmacologyGABAA-rho receptor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCRE RECOMBINASE EXPRESSIONmedicinePharmacology (medical)Pharmacology & PharmacyReceptorPARVALBUMIN-POSITIVE INTERNEURONSIN-VIVOOriginal ResearchPregnanolonePharmacologyScience & TechnologyGABAA receptorAllopregnanolonelcsh:RM1-950POINT MUTATIONA RECEPTORS3. Good health030104 developmental biologymedicine.anatomical_structurelcsh:Therapeutics. Pharmacologychemistrynervous systemPurkinje cellsALLOPREGNANOLONEextrasynaptic GABAA receptorsmotor performance1115 Pharmacology And Pharmaceutical Sciences3111 BiomedicineneurosteroidsLife Sciences & Biomedicine030217 neurology & neurosurgeryextrasynaptic GABA(A) receptors
researchProduct

The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy

2021

Signal transducer and activator of transcription (STAT) 3 is one of the most complex regulators of transcription. Constitutive activation of STAT3 has been reported in many types of tumors and depends on mechanisms such as hyperactivation of receptors for pro-oncogenic cytokines and growth factors, loss of negative regulation, and excessive cytokine stimulation. In contrast, somatic STAT3 mutations are less frequent in cancer. Several oncogenic targets of STAT3 have been recently identified such as c-myc, c-Jun, PLK-1, Pim1/2, Bcl-2, VEGF, bFGF, and Cten, and inhibitors of STAT3 have been developed for cancer prevention and treatment. However, despite the oncogenic role of STAT3 having been…

0301 basic medicineGene isoformSTAT3 Transcription FactorCarcinogenesistumor suppressorPIM1Antineoplastic AgentsReviewBiologyCatalysisstatInorganic ChemistrySTAT3lcsh:Chemistry03 medical and health sciences0302 clinical medicineNeoplasmsDrug DiscoverymedicineAnimalsHumanscancerNeoplasm InvasivenessMolecular Targeted TherapyPhysical and Theoretical ChemistrySTAT3Molecular BiologyTranscription factorlcsh:QH301-705.5SpectroscopyNeovascularization PathologicOrganic ChemistryAlternative splicingtumor promoterCancerGeneral Medicinemedicine.diseaseComputer Science ApplicationsGene Expression Regulation Neoplastic030104 developmental biologylcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisCancer researchbiology.proteinSTAT proteinInternational Journal of Molecular Sciences
researchProduct